tirzepatide glaucoma Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort Comparative ocular outcomes of tirzepatide
Description
If tirzepatide is not effective, mazdutide may work better due to its different secondary mechanism, and vice versa
The shortage justification is gone
Time in restorative deep sleep increases
Only a healthcare professional can provide the proper guidance on whether to stop or continue the medication
Rapid improvement in glycemic control has been associated with temporary worsening of diabetic retinopathy
